FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120285013> ?p ?o ?g. }

• W3120285013 endingPage "S645" @default.
• W3120285013 startingPage "S645" @default.
• W3120285013 abstract "Abstract Background Despite the implementation of successful antibiotic stewardship programs, antibiotic resistance continue to emerge particularly against gram-negative bacteria. With the increase use of antibiotics in high risk patients with hematological malignancies, the empiric therapy with standard antibiotic could be inappropriate. New antibiotics may be useful to cover potential resistant pathogens. We evaluated the role of a new cephalosporin /β-lactamase inhibitor ceftolozane-tazobactam (C/T) in comparison to standard of care (SOC) antibiotics in the empiric treatment of febrile neutropenic cancer patients with hematological malignancies. Methods We conducted a prospective randomized open label comparative study to evaluate the safety and efficacy of C/T vs SOC antibiotics consisting of cefepime, piperacillin-tazobactam or meropenem when used in combination with gram positive antibacterial agents. Between May 2018 and March 2020, we enrolled 88 febrile neutropenic patients with hematological malignancies who presented to our emergency center. Patients received at least 72 hours of intravenous study drugs and were followed through end of IV therapy and for up to 42 days. Results A total of 88 patients were analyzed of whom 42 received C/T and 46 SOC antimicrobial agents. The rate of documented bloodstream infections was similar in both groups (CE-TZ 21% vs SOC 26%, p=0.61). Favorable clinical response at end of IV therapy was significantly better in the C/T arm compared to SOC therapy (88% vs 72%, p=0.039), at test of cure (21 days), and last follow-up (42 days). In patients with documented infections, the rate of microbiological eradication was similar in both groups. Drug-related adverse events that led to drug discontinuation was similar in both groups (7%). Similarly overall mortality was similar in both groups. Conclusion The empiric use of C/T to cover gram negative organisms in high risk febrile neutropenic patients with hematological malignancies is safe and associated with better clinical outcome than SOC antimicrobial agents. The emergence of resistant pathogens should be further evaluated. Disclosures Issam I. Raad, MD, Citius (Other Financial or Material Support, Ownership interest)Cook Medical (Grant/Research Support)Inventive Protocol (Other Financial or Material Support, Ownership interest)Novel Anti-Infective Technologies (Shareholder, Other Financial or Material Support, Ownership interest)" @default.
• W3120285013 created "2021-01-18" @default.
• W3120285013 creator A5007730121 @default.
• W3120285013 creator A5013302356 @default.
• W3120285013 creator A5014449432 @default.
• W3120285013 creator A5022649229 @default.
• W3120285013 creator A5027019706 @default.
• W3120285013 creator A5033841614 @default.
• W3120285013 creator A5044003984 @default.
• W3120285013 creator A5050620863 @default.
• W3120285013 creator A5053146342 @default.
• W3120285013 creator A5083755423 @default.
• W3120285013 date "2020-10-01" @default.
• W3120285013 modified "2023-10-03" @default.
• W3120285013 title "1257. A phase II Prospective Randomized Study to Assess Ceftolozane-Tazobactam in the Management of Febrile Neutropenia in Patients with Hematological Malignancies" @default.
• W3120285013 doi "https://doi.org/10.1093/ofid/ofaa439.1441" @default.
• W3120285013 hasPublicationYear "2020" @default.
• W3120285013 type Work @default.
• W3120285013 sameAs 3120285013 @default.
• W3120285013 citedByCount "0" @default.
• W3120285013 crossrefType "journal-article" @default.
• W3120285013 hasAuthorship W3120285013A5007730121 @default.
• W3120285013 hasAuthorship W3120285013A5013302356 @default.
• W3120285013 hasAuthorship W3120285013A5014449432 @default.
• W3120285013 hasAuthorship W3120285013A5022649229 @default.
• W3120285013 hasAuthorship W3120285013A5027019706 @default.
• W3120285013 hasAuthorship W3120285013A5033841614 @default.
• W3120285013 hasAuthorship W3120285013A5044003984 @default.
• W3120285013 hasAuthorship W3120285013A5050620863 @default.
• W3120285013 hasAuthorship W3120285013A5053146342 @default.
• W3120285013 hasAuthorship W3120285013A5083755423 @default.
• W3120285013 hasBestOaLocation W31202850131 @default.
• W3120285013 hasConcept C126322002 @default.
• W3120285013 hasConcept C142724271 @default.
• W3120285013 hasConcept C177713679 @default.
• W3120285013 hasConcept C204787440 @default.
• W3120285013 hasConcept C2776694085 @default.
• W3120285013 hasConcept C2777050379 @default.
• W3120285013 hasConcept C2777063308 @default.
• W3120285013 hasConcept C2777637488 @default.
• W3120285013 hasConcept C2777858937 @default.
• W3120285013 hasConcept C2778193466 @default.
• W3120285013 hasConcept C2778266534 @default.
• W3120285013 hasConcept C2778850193 @default.
• W3120285013 hasConcept C2779181126 @default.
• W3120285013 hasConcept C2779375183 @default.
• W3120285013 hasConcept C2779631663 @default.
• W3120285013 hasConcept C501593827 @default.
• W3120285013 hasConcept C523546767 @default.
• W3120285013 hasConcept C54355233 @default.
• W3120285013 hasConcept C71924100 @default.
• W3120285013 hasConcept C86803240 @default.
• W3120285013 hasConcept C89423630 @default.
• W3120285013 hasConcept C94665300 @default.
• W3120285013 hasConceptScore W3120285013C126322002 @default.
• W3120285013 hasConceptScore W3120285013C142724271 @default.
• W3120285013 hasConceptScore W3120285013C177713679 @default.
• W3120285013 hasConceptScore W3120285013C204787440 @default.
• W3120285013 hasConceptScore W3120285013C2776694085 @default.
• W3120285013 hasConceptScore W3120285013C2777050379 @default.
• W3120285013 hasConceptScore W3120285013C2777063308 @default.
• W3120285013 hasConceptScore W3120285013C2777637488 @default.
• W3120285013 hasConceptScore W3120285013C2777858937 @default.
• W3120285013 hasConceptScore W3120285013C2778193466 @default.
• W3120285013 hasConceptScore W3120285013C2778266534 @default.
• W3120285013 hasConceptScore W3120285013C2778850193 @default.
• W3120285013 hasConceptScore W3120285013C2779181126 @default.
• W3120285013 hasConceptScore W3120285013C2779375183 @default.
• W3120285013 hasConceptScore W3120285013C2779631663 @default.
• W3120285013 hasConceptScore W3120285013C501593827 @default.
• W3120285013 hasConceptScore W3120285013C523546767 @default.
• W3120285013 hasConceptScore W3120285013C54355233 @default.
• W3120285013 hasConceptScore W3120285013C71924100 @default.
• W3120285013 hasConceptScore W3120285013C86803240 @default.
• W3120285013 hasConceptScore W3120285013C89423630 @default.
• W3120285013 hasConceptScore W3120285013C94665300 @default.
• W3120285013 hasIssue "Supplement_1" @default.
• W3120285013 hasLocation W31202850131 @default.
• W3120285013 hasLocation W31202850132 @default.
• W3120285013 hasLocation W31202850133 @default.
• W3120285013 hasOpenAccess W3120285013 @default.
• W3120285013 hasPrimaryLocation W31202850131 @default.
• W3120285013 hasRelatedWork W1559516092 @default.
• W3120285013 hasRelatedWork W1999059251 @default.
• W3120285013 hasRelatedWork W2089410660 @default.
• W3120285013 hasRelatedWork W2164302723 @default.
• W3120285013 hasRelatedWork W2165649009 @default.
• W3120285013 hasRelatedWork W2225659496 @default.
• W3120285013 hasRelatedWork W3119408265 @default.
• W3120285013 hasRelatedWork W3120285013 @default.
• W3120285013 hasRelatedWork W4235067922 @default.
• W3120285013 hasRelatedWork W4255172204 @default.
• W3120285013 hasVolume "7" @default.
• W3120285013 isParatext "false" @default.
• W3120285013 isRetracted "false" @default.
• W3120285013 magId "3120285013" @default.
• W3120285013 workType "article" @default.